Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

Hyunji Lee; Sungjin Park; Gyeyeong Kong; So Hee Kwon; Jisoo Park; Jongsun Park; Seon Hwan Kim

doi:10.1007/s43188-022-00129-1

Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

Hyunji Lee, Sungjin Park, Gyeyeong Kong, So Hee Kwon, Jisoo Park, Jongsun Park, Seon Hwan Kim

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Phosphodiesterase 11A (PDE11A), a 3′,5′-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

Original language	English
Pages (from-to)	409-415
Number of pages	7
Journal	Toxicological Research
Volume	38
Issue number	3
DOIs	https://doi.org/10.1007/s43188-022-00129-1
Publication status	Published - 2022 Jul

Bibliographical note

Funding Information:
This study was funded by Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611).

Funding Information:
This work was financially supported by a research fund from Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/cNOwdf .

Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Korean Society of Toxicology.

All Science Journal Classification (ASJC) codes

Toxicology
Health, Toxicology and Mutagenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s43188-022-00129-1

Cite this

@article{0dadd3d76cf449c08cf75f9be4f8d56d,

title = "Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma",

abstract = "Phosphodiesterase 11A (PDE11A), a 3′,5′-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.",

author = "Hyunji Lee and Sungjin Park and Gyeyeong Kong and Kwon, {So Hee} and Jisoo Park and Jongsun Park and Kim, {Seon Hwan}",

note = "Funding Information: This study was funded by Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). Funding Information: This work was financially supported by a research fund from Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/cNOwdf . Publisher Copyright: {\textcopyright} 2022, The Author(s) under exclusive licence to Korean Society of Toxicology.",

year = "2022",

month = jul,

doi = "10.1007/s43188-022-00129-1",

language = "English",

volume = "38",

pages = "409--415",

journal = "Toxicological Research",

issn = "1976-8257",

publisher = "Koreal Association of Medical Journal Editors",

number = "3",

}

TY - JOUR

T1 - Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

AU - Lee, Hyunji

AU - Park, Sungjin

AU - Kong, Gyeyeong

AU - Kwon, So Hee

AU - Park, Jisoo

AU - Park, Jongsun

AU - Kim, Seon Hwan

N1 - Funding Information: This study was funded by Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). Funding Information: This work was financially supported by a research fund from Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/cNOwdf . Publisher Copyright: © 2022, The Author(s) under exclusive licence to Korean Society of Toxicology.

PY - 2022/7

Y1 - 2022/7

N2 - Phosphodiesterase 11A (PDE11A), a 3′,5′-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

AB - Phosphodiesterase 11A (PDE11A), a 3′,5′-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

UR - http://www.scopus.com/inward/record.url?scp=85127944890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127944890&partnerID=8YFLogxK

U2 - 10.1007/s43188-022-00129-1

DO - 10.1007/s43188-022-00129-1

M3 - Article

AN - SCOPUS:85127944890

SN - 1976-8257

VL - 38

SP - 409

EP - 415

JO - Toxicological Research

JF - Toxicological Research

IS - 3

ER -